3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
3
Gynecologic
2
Genitourinary
2
Dermatologic
2
Breast
1
Conditions
Melanoma
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
70
Nivolumab
47
Ipilimumab
27
Specimen Handling
15
Magnetic Resonance Spectroscopy
15
trametinib
14
Biopsy
13
dabrafenib
11
cemiplimab
11
avelumab
11
Cyclophosphamide
11
binimetinib
10
Radiotherapy
9
CTLA-4 Antigen
9
fludarabine
8
encorafenib
7
atezolizumab
7
Radiosurgery
7
Immunoglobulin G
7
Disulfides
7
Cisplatin
7
fludarabine phosphate
6
durvalumab
6
tislelizumab
5
relatlimab
5
lenvatinib
5
dostarlimab
5
Pemetrexed
5
Paclitaxel
5
Introns
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Saline Solution
×
Dermatologic
×
Clear all
NCT03271372
2026-05-12
ADAM
University of Washington
Phase 3
Active not recruiting
101 enrolled
NCT05933577
2025-09-24
V940-001
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
1,089 enrolled